Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 2 Years after Full Rollout, Sakigake System Shows Tepid Uptake as Industry Sees Poor Incentives
September 21, 2022
- MHLW Retools New Expert Panel, Industry Hearing Set for Sept. 22
September 21, 2022
- MHLW Eyes Diet Submission of Bill to Amend Cannabis Control Act Next Year: Official
September 20, 2022
- Japan Detects 14 More Probable Cases of Pediatric Hepatitis
September 20, 2022
- Japan OKs Additional Indications for 12 Fertility Treatments
September 20, 2022
- Moderna in Talks with Govt on Building Vaccine Plant in Japan: CEO
September 16, 2022
- Govt’s Economic Security Panel Discusses Plan for Supply Chain Survey
September 16, 2022
- MHLW to Submit Bill for Integrating Drug Supply Info in Extraordinary Diet Session: Official
September 15, 2022
- MHLW to Simplify Optimal-Use Guidelines for Drugs after Reexamination Period
September 15, 2022
- Contraindication Lifted for Concurrent Use of Adempas and HIV Protease Inhibitors
September 14, 2022
- Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
September 13, 2022
- MHLW Panel Recognizes 2 More Deaths Linked to COVID Jabs
September 13, 2022
- MHLW to Survey Impact of Price Surge, FX on Drugs with High Need for Stable Supply
September 13, 2022
- MHLW Panels’ Decision to Put a Hold on Shionogi’s COVID Pill Based on Regulatory Science: Official
September 12, 2022
- LDP Project Team Proposes Deeper Discussions on Structural Drug Pricing Issues
September 12, 2022
- Govt Laments AnGes’ Aborted COVID Vaccine Project, Renews Pledge to Back Potential Seeds
September 12, 2022
- PMDA Reviewing New Safety Risks for Itraconazole, I/O Drugs and More
September 12, 2022
- PMDA Sets 1st “GMP Roundtable” with Academia, Industry in November
September 12, 2022
- Japan to End Govt-Controlled Supply of Lagevrio on Sept. 15: MHLW
September 12, 2022
- Japan to Boost Number of HPV Vaccination Base Hospitals
September 9, 2022
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…